Study Evaluating MYO-029 in Adult Muscular Dystrophy

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00104078

Enrollment

108

Registered

2005-02-23

Start date

2005-02-28

Completion date

2007-01-31

Last updated

2007-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Limb-Girdle Muscular Dystrophy

Brief summary

The purpose of this phase I/II, multicenter, safety trial is to study MYO-029 in adult patients with muscular dystrophy.

Interventions

DRUGMYO-029

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Written informed consent. * Confirmed clinical and molecular diagnosis of Becker Muscular Dystrophy (BMD), Facioscapulohumeral Muscular Dystrophy (FSHD), or Limb-Girdle Muscular Dystrophy (LGMD) * Independently ambulatory

Exclusion criteria

* Patients with certain clinical conditions * Patients using steroids or other medications with the potential to affect muscle function * History of sensitivity to monoclonal antibodies or protein pharmaceuticals * Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
Safety assessment	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026